[
    {
        "pregunta": "1. Why should screening for ILD not be limited only to patients with identified risk factors in systemic autoimmune rheumatic diseases (SARDs)?",
        "respuesta": "Screening for interstitial lung disease (ILD) in patients with systemic autoimmune rheumatic diseases (SARDs) should not be limited only to those with identified risk factors because ILD can be present even in patients without obvious risk factors or symptoms. Early detection of ILD is crucial as it may be asymptomatic initially but can lead to significant morbidity and mortality if untreated. Routine screening allows for timely diagnosis and management, potentially improving outcomes and preventing irreversible lung damage."
    },
    {
        "pregunta": "2. Which screening methods are conditionally recommended against for ILD in SARD patients?",
        "respuesta": "Screening methods conditionally recommended against for interstitial lung disease (ILD) in systemic autoimmune rheumatic disease (SARD) patients typically include routine use of high-resolution computed tomography (HRCT) scans in asymptomatic patients without any pulmonary symptoms or abnormal pulmonary function tests, due to concerns about radiation exposure and cost-effectiveness. Additionally, routine invasive procedures like bronchoscopy for screening purposes are generally not recommended. However, specific guidelines may vary, so clinical judgment and individual risk assessment remain important."
    },
    {
        "pregunta": "3. What systemic manifestations in mixed connective tissue disease (MCTD) are associated with higher ILD risk?",
        "respuesta": "In mixed connective tissue disease (MCTD), systemic manifestations associated with a higher risk of interstitial lung disease (ILD) include Raynaud's phenomenon, swollen hands, arthritis, myositis, and esophageal dysmotility. Additionally, the presence of anti-U1 RNP antibodies and features overlapping with systemic sclerosis or polymyositis can also indicate increased ILD risk."
    },
    {
        "pregunta": "4. Why is screening with chest radiography conditionally recommended against in patients with SARDs at risk for ILD?",
        "respuesta": "Screening with chest radiography is conditionally recommended against in patients with systemic autoimmune rheumatic diseases (SARDs) at risk for interstitial lung disease (ILD) because chest X-rays have limited sensitivity for early or mild ILD. They may miss subtle lung changes, leading to false reassurance or delayed diagnosis. More sensitive imaging modalities, such as high-resolution computed tomography (HRCT), are preferred for accurate detection. Therefore, routine chest radiography is not recommended as a screening tool in this population."
    },
    {
        "pregunta": "5. How does the progression and monitoring frequency of rheumatoid arthritis-associated ILD (RA-ILD) differ from that of other SARD-ILDs?",
        "respuesta": "Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) often has a more variable and potentially slower progression compared to other systemic autoimmune rheumatic disease-associated ILDs (SARD-ILDs), such as those seen in systemic sclerosis or idiopathic inflammatory myopathies, which may progress more rapidly. Consequently, the monitoring frequency for RA-ILD is typically individualized based on disease severity and progression risk but generally involves regular clinical assessments and pulmonary function tests (PFTs) every 3 to 6 months initially, then possibly less frequently if stable. In contrast, other SARD-ILDs with more aggressive courses may require more frequent monitoring, including imaging and PFTs every 3 months or sooner, to promptly detect progression and adjust treatment."
    },
    {
        "pregunta": "6. How does disease activity in SARDs influence the monitoring frequency of associated ILD?",
        "respuesta": "In systemic autoimmune rheumatic diseases (SARDs), increased disease activity is associated with a higher risk of progression or exacerbation of associated interstitial lung disease (ILD). Therefore, patients with active SARDs typically require more frequent monitoring of their ILD to detect changes early, guide treatment adjustments, and prevent irreversible lung damage. Conversely, in patients with stable or low disease activity, monitoring intervals may be extended. Monitoring usually involves clinical assessment, pulmonary function tests, and imaging studies such as high-resolution CT scans, tailored to disease severity and activity."
    },
    {
        "pregunta": "7. Why is the 6-minute walk distance (6MWD) test conditionally recommended against for routine monitoring in patients with SARD-ILD?",
        "respuesta": "The 6-minute walk distance (6MWD) test is conditionally recommended against for routine monitoring in patients with systemic autoimmune rheumatic disease-associated interstitial lung disease (SARD-ILD) because it has limited sensitivity and specificity in detecting disease progression or response to therapy in this population. Additionally, factors unrelated to lung function, such as musculoskeletal involvement, fatigue, and motivation, can influence test results, reducing its reliability as a sole monitoring tool. Therefore, its routine use is not strongly supported for tracking SARD-ILD over time."
    },
    {
        "pregunta": "8. What are the recommended screening tests for ILD in patients with SARDs at increased risk?",
        "respuesta": "Recommended screening tests for interstitial lung disease (ILD) in patients with systemic autoimmune rheumatic diseases (SARDs) at increased risk typically include:\n\n1. **High-resolution computed tomography (HRCT) of the chest** – the gold standard for detecting ILD.\n2. **Pulmonary function tests (PFTs)** – including spirometry, lung volumes, and diffusing capacity for carbon monoxide (DLCO) to assess lung function.\n3. **Clinical assessment** – evaluation for respiratory symptoms such as dyspnea and cough.\n4. **Chest X-ray** – though less sensitive, may be used as an initial screening tool.\n5. **Laboratory tests** – including serologic markers relevant to SARDs that may correlate with ILD risk.\n\nRegular screening intervals depend on the specific SARD, disease activity, and risk factors."
    },
    {
        "pregunta": "9. How often are PFTs suggested for monitoring ILD progression in patients with idiopathic inflammatory myopathy-associated ILD (IIM-ILD) and systemic sclerosis-associated ILD (SSc-ILD) during the first year?",
        "respuesta": "Pulmonary function tests (PFTs) are generally recommended every 3 to 6 months during the first year for monitoring ILD progression in patients with idiopathic inflammatory myopathy-associated ILD (IIM-ILD) and systemic sclerosis-associated ILD (SSc-ILD). This frequency helps to closely track disease activity and guide treatment decisions."
    },
    {
        "pregunta": "10. What monitoring methods are conditionally recommended against for ILD progression in patients with SARDs-ILD?",
        "respuesta": "Monitoring methods conditionally recommended against for ILD progression in patients with SARDs-ILD (systemic autoimmune rheumatic diseases-associated interstitial lung disease) typically include invasive procedures like routine bronchoscopy or frequent lung biopsies, due to their risks and limited additional benefit in routine monitoring. Additionally, reliance solely on pulmonary function tests without imaging or clinical correlation may be discouraged. However, specific guideline recommendations can vary, so it's important to refer to the latest consensus statements for detailed guidance."
    },
    {
        "pregunta": "11. What factors influence the frequency of monitoring in patients with SARD-ILD?",
        "respuesta": "The frequency of monitoring in patients with systemic autoimmune rheumatic disease-associated interstitial lung disease (SARD-ILD) is influenced by several factors, including:\n\n1. **Disease severity and progression rate:** More severe or rapidly progressing ILD requires more frequent monitoring.\n2. **Type of underlying autoimmune disease:** Different SARDs (e.g., systemic sclerosis, rheumatoid arthritis) have variable ILD courses influencing monitoring intervals.\n3. **Baseline lung function:** Patients with impaired or declining pulmonary function tests (PFTs) need closer follow-up.\n4. **Radiologic findings:** Extent and pattern of ILD on high-resolution CT scans guide monitoring frequency.\n5. **Treatment regimen and response:** Patients on immunosuppressive therapy or with recent treatment changes require more frequent assessments.\n6. **Symptoms and clinical status:** New or worsening respiratory symptoms prompt increased monitoring.\n7. **Comorbidities and risk factors:** Presence of other lung conditions or risk factors may necessitate closer observation.\n\nMonitoring typically includes clinical evaluation, PFTs, and imaging at intervals tailored to these factors."
    },
    {
        "pregunta": "12. In what clinical situations might ambulatory desaturation testing be considered for patients with SARDs?",
        "respuesta": "Ambulatory desaturation testing in patients with systemic autoimmune rheumatic diseases (SARDs) may be considered when there is suspicion of interstitial lung disease (ILD), pulmonary hypertension, or other pulmonary complications that cause exertional hypoxemia. It is particularly useful in patients who report dyspnea on exertion despite normal resting oxygen saturation, to detect exercise-induced oxygen desaturation that may not be evident at rest. This testing helps guide diagnosis, assess disease severity, and monitor response to therapy."
    },
    {
        "pregunta": "13. How do the recommendations differ between screening and monitoring strategies for ILD in patients with systemic autoimmune rheumatic diseases?",
        "respuesta": "Screening strategies for interstitial lung disease (ILD) in patients with systemic autoimmune rheumatic diseases (SARDs) focus on early detection in asymptomatic individuals, typically recommending baseline assessments such as pulmonary function tests (PFTs), high-resolution computed tomography (HRCT) scans, and clinical evaluation at diagnosis or early in the disease course. The goal is to identify ILD before clinical symptoms arise to allow timely intervention.\n\nMonitoring strategies, on the other hand, are applied to patients with known ILD or those at high risk, emphasizing regular follow-up to assess disease progression or treatment response. Monitoring recommendations typically include periodic PFTs, symptom review, and repeat HRCT at intervals guided by clinical status, with adjustments based on changes in lung function or imaging findings.\n\nIn summary, screening aims at early identification in all at-risk patients, usually with a one-time or baseline assessment, while monitoring involves ongoing evaluation in patients with established ILD or high risk, using serial tests to guide management."
    },
    {
        "pregunta": "14. How does the combination of HRCT and PFTs compare to PFTs alone for screening patients at increased risk of ILD?",
        "respuesta": "The combination of high-resolution computed tomography (HRCT) and pulmonary function tests (PFTs) is more effective than PFTs alone for screening patients at increased risk of interstitial lung disease (ILD). HRCT can detect early or subtle parenchymal abnormalities that may not yet cause measurable changes in lung function, while PFTs assess functional impairment. Together, they improve sensitivity and allow for earlier and more accurate identification of ILD compared to using PFTs alone."
    },
    {
        "pregunta": "15. What are the advantages and limitations of using PFTs for monitoring ILD progression in SARD patients?",
        "respuesta": "Pulmonary function tests (PFTs) are valuable tools for monitoring interstitial lung disease (ILD) progression in systemic autoimmune rheumatic disease (SARD) patients. \n\n**Advantages:**\n- **Non-invasive and repeatable:** PFTs can be performed regularly without risk to the patient.\n- **Quantitative assessment:** They provide objective measures of lung function, such as forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO), which reflect restrictive lung disease and gas exchange impairment.\n- **Early detection of functional decline:** PFTs can detect subtle changes before clinical symptoms worsen.\n- **Guiding treatment decisions:** Trends in PFT results help clinicians adjust therapy and monitor response.\n\n**Limitations:**\n- **Variability:** Results can be influenced by patient effort and technician technique, leading to variability.\n- **Lack of specificity:** Changes in PFTs may not distinguish ILD progression from other lung or cardiac comorbidities.\n- **Insensitive to early structural changes:** PFTs may remain normal despite early radiographic or histologic lung involvement.\n- **Limited information on disease pattern:** PFTs do not provide anatomical details or extent of fibrosis, which imaging studies reveal.\n\nIn summary, while PFTs are essential for functional monitoring of ILD in SARD patients, they should be used in conjunction with clinical assessment and imaging for comprehensive evaluation."
    },
    {
        "pregunta": "16. What criteria might prompt a clinician to perform HRCT in a patient with SARDs-ILD, despite the lack of specific guidance on routine frequency?",
        "respuesta": "Clinicians might perform HRCT in patients with systemic autoimmune rheumatic diseases-associated interstitial lung disease (SARDs-ILD) despite the lack of specific routine frequency guidelines when there is clinical suspicion of disease progression or complication. Criteria prompting HRCT include worsening respiratory symptoms (e.g., increased dyspnea or cough), declining pulmonary function tests (such as reduced FVC or DLCO), new or worsening abnormalities on chest X-ray, or suspicion of infection, drug toxicity, or pulmonary hypertension. HRCT helps in assessing disease extent, activity, and guiding management decisions."
    },
    {
        "pregunta": "17. Why is chest radiography not recommended as a screening test for ILD in patients with SARDs?",
        "respuesta": "Chest radiography is not recommended as a screening test for interstitial lung disease (ILD) in patients with systemic autoimmune rheumatic diseases (SARDs) because it has low sensitivity for detecting early or mild ILD. It often fails to reveal subtle interstitial changes that high-resolution computed tomography (HRCT) can detect, leading to underdiagnosis. Therefore, HRCT is preferred for more accurate and early identification of ILD in this population."
    },
    {
        "pregunta": "18. What screening method is conditionally recommended over history and physical examination alone for patients with SARDs at increased ILD risk?",
        "respuesta": "High-resolution computed tomography (HRCT) is conditionally recommended over history and physical examination alone for screening patients with systemic autoimmune rheumatic diseases (SARDs) who are at increased risk of interstitial lung disease (ILD)."
    },
    {
        "pregunta": "19. Why might patients with Sjögren’s syndrome-associated ILD (SjD-ILD) require varied monitoring frequencies?",
        "respuesta": "Patients with Sjögren’s syndrome-associated interstitial lung disease (SjD-ILD) may require varied monitoring frequencies because the disease course can be highly variable. Some patients experience stable or slowly progressive lung involvement, while others may have rapidly progressive or fluctuating symptoms. Additionally, the severity of lung involvement, response to treatment, presence of comorbidities, and risk of complications can differ among individuals, necessitating tailored follow-up intervals to effectively manage disease progression and optimize outcomes."
    },
    {
        "pregunta": "20. In which clinical scenarios is the 6MWD considered a useful marker for monitoring ILD progression?",
        "respuesta": "The 6-minute walk distance (6MWD) is considered a useful marker for monitoring disease progression in interstitial lung disease (ILD), particularly in idiopathic pulmonary fibrosis (IPF) and other fibrotic ILDs. It is valuable in clinical scenarios where assessing functional exercise capacity and detecting changes over time are important, such as:\n\n- Evaluating baseline functional status and prognosis in patients with IPF and other fibrotic ILDs.\n- Monitoring disease progression and response to treatment.\n- Assessing functional impairment in connective tissue disease-associated ILD.\n- Detecting exercise-induced desaturation and guiding supplemental oxygen therapy.\n\nOverall, the 6MWD provides a practical, reproducible measure of functional status and correlates with morbidity and mortality in ILD patients."
    }
]